We found no associations between baseline serum BAFF levels in patients with later clinical response after rituximab therapy versus non-responders, and no differences in baseline BAFF levels in ME/CFS patients of different clinical severity. This evidence concerns the gene TNFSF13B and myalgic encephalomeyelitis/chronic fatigue syndrome.